J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523258-15-00

Enrollment

285

Registered

2026-07-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Brief summary

Change from Baseline in Antigen Kiel (Ki-67) Expression., Rate of Symptomatic Ovarian Cysts.

Interventions

DRUGTAMOXIFEN

DRUGGOSERELIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Antigen Kiel (Ki-67) Expression., Rate of Symptomatic Ovarian Cysts.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 22, 2026